Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Theraclone Sciences Announces Universal Therapeutic Antibody for Influenza A Demonstrates Reductions in Clinical Symptoms Score and Viral Load in a Phase 2a Human Viral Challenge Study

09:00 EDT 8 Sep 2013 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced results from a Phase 2a viral challenge study of TCN-032 for the universal treatment of influenza A. The results of this study ...

Other Sources for this Article

MacDougall Biomedical Communications
Doug MacDougall or Michelle Avery, 781-235-3060

NEXT ARTICLE

More From BioPortfolio on "Theraclone Sciences Announces Universal Therapeutic Antibody for Influenza A Demonstrates Reductions in Clinical Symptoms Score and Viral Load in a Phase 2a Human Viral Challenge Study"

Search BioPortfolio: